Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03199339 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371

A Phase 1 study, sponsored by Global Alliance for TB Drug Development.

Completed
Registry status
Phase 1
Development phase
74
Enrollment target

NCT03199339: Completed Phase 1 study, sponsored by Global Alliance for TB Drug Development.

NCT03199339 is a Phase 1 study that has completed, run by Global Alliance for TB Drug Development. The registered enrollment target is 74 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03199339, a Phase 1 study, has completed, sponsored by Global Alliance for TB Drug Development.

COMPLETED
Registry status
Phase 1
Development phase
74 participants
Enrollment target

Study Summary

The primary objective of the study is to evaluate the safety and tolerability of single and multiple doses of TBA-7371 in healthy subjects

Primary Outcome

The primary endpoint of the study will be the number and severity of treatment emergent adverse events (TEAEs) following single doses of TBA-7371 and placebo

Interventions

  • DRUG Placebo
  • DRUG TBA-7371

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2017-08-29
Est. Completion 2018-07-08
Phase Phase 1

What the finished NCT03199339 record still lists

NCT03199339 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03199339 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03199339 about?

NCT03199339 is a clinical study titled "A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371". The primary objective of the study is to evaluate the safety and tolerability of single and multiple doses of TBA-7371 in healthy subjects

What is the current status of trial NCT03199339?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2017-08-29. Estimated completion is 2018-07-08.

What interventions are being tested in trial NCT03199339?

The interventions under investigation include: Placebo (DRUG), TBA-7371 (DRUG).

Who is sponsoring clinical trial NCT03199339?

This trial is sponsored by Global Alliance for TB Drug Development, which has 13 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03199339's enrollment target sits among peer trials

74 725th of 2000 higher than 1,269 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03422731 · 74 participants · Early Phase 1

    Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

  • NCT03804853 · 74 participants · NA

    Rehabilitation Following Reverse Total Shoulder Arthroplasty

  • NCT04065776 · 74 participants · NA

    Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

  • NCT04771156 · 74 participants · Phase 4

    Ketorolac in Palatoplasty

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03199339, the US trial registry maintained by the National Library of Medicine. NCT03199339 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.